Two Drug ART? — Clinical Considerations

Volume 5, Issue 2

Two Drug ART? — Clinical Considerations

In this issue:

In her recent newsletter issue (eHIV Review V5 #1), Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzed the current research about the potential uses of two-drug ART regimens. Join her now for a case-based discussion about how that new information can affect patient selection in the clinic.

Learning objectives:

Identify appropriate and inappropriate patients and circumstances for a two-drug regimen as initial therapy.
Describe appropriate and inappropriate patients and circumstances for two-drug regimen switch or maintenance therapy.

Author:

Ethel D. Weld, MD, PhD

Associate Professor of Medicine, Physiology, Pharmacology & Therapeutics
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Guest Faculty Disclosures

Dr. Weld has indicated that she has no financial interests or relationships with a commercial entity.

Unlabeled/Unapproved Uses

Dr. Weld has disclosed that she has any no relationship with any product or service relevant to today’s discussion. She has indicated that she will be referencing the unlabeled or unapproved use of combination agents currently being investigated in ongoing studies and trials. These include dolutegravir plus cobicistat-boosted darunavir, dolutegravir plus lamivudine, lamivudine plus ritonavir-boosted darunavir, and long-acting injectable ART with cabotegravir-long-acting and rilpivirine long-acting.

Program Directors:

Ethel D. Weld, MD, PhD

Associate Professor of Medicine, Physiology, Pharmacology & Therapeutics
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Guest Faculty Disclosures:

Dr. Weld has indicated that she has no financial interests or relationships with a commercial entity.

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: December 23, 2019
Expiration date: December 22, 2021

Start Issue